Lymphoid gene expression as a predictor of risk of secondary brain tumors

Genes Chromosomes and Cancer

Volumn 42, Issue 2, 2005, Pages 107-116

  Edick, Mathew J ^a   Cheng, Cheng ^a   Yang, Wenjian ^a   Cheok, Meyling ^a   Wilkinson, Mark R ^a   Pei, Deqing ^a   Evans, William E ^a,b   Kun, Larry E ^a,b   Pui, Ching Hon ^a,b   Relling, Mary V ^a,b,c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIMETABOLITE; CCAAT ENHANCER BINDING PROTEIN; FIBROBLAST GROWTH FACTOR 1; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN L; KARYOPHERIN BETA; NUCLEAR FACTOR I; STAT4 PROTEIN; THIOPURINE METHYLTRANSFERASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BRAIN TUMOR; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DNA POLYMORPHISM; FEMALE; GENE CLUSTER; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE PROBE; GENETIC RISK; GERM LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; LYMPHOID TISSUE; MALE; PRIORITY JOURNAL; PROBABILITY; REGRESSION ANALYSIS; SKULL IRRADIATION;

ADOLESCENT; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; NEOPLASMS, RADIATION-INDUCED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS;

EID: 19944426691     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.20121     Document Type: Article

References (56)

1. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD, Sallan SE, Lander ES, Golub TR, Korsmeyer SJ. 2002. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 30:41-47.
2. Baria K, Warren C, Roberts SA, West CM, Evans DG, Varley JM, Scott D. 2000. Correspondence re: A. Rothfuss et al., Induced micronucleus frequencies in peripheral blood lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families. Cancer Res 60:390-394.
3. Baria K, Warren C, Roberts SA, West CM, Scott D. 2001. Chromosomal radiosensitivity as a marker of predisposition to common cancers? Br J Cancer 84:892-896.
4. Berwick M, Vineis P. 2000. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst 92:874-897.
5. Bhatia S, Sklar C. 2001. Second cancers in survivors of childhood cancer. Nat Rev Cancer 2:124-132.
6. Bratt O. 2002. Hereditary prostate cancer: clinical aspects. J Urol 168:906-913.
7. Brenner DJ, Doll R. Goodhead DT, Hall EJ, Land CE, Little JB, Lubin JH, Preston DL, Preston RJ, Puskin JS, Ron E, Sachs RK, Samet JM, Setlow RB, Zaider M. 2003. Cancer risks attributable to low doses of ionizing radiation: assessing what we really know. Proc Natl Acad Sci USA 100:13761-13766.
8. Buchholz TA, Wu X. 2001. Radiation-induced chromatid breaks as a predictor of breast cancer risk. Int J Radiat Oncol Biol Phys 49:533-537.
9. Cheung VG, Conlin LK, Weber TM, Arcaro M, Jen KY, Morley M, Spielman RS. 2003. Natural variation in human gene expression assessed in lymphoblastoid cells. Nat Genet 33:422-425.
10. Dornfeld KJ, Lawrence TS. 2001. A predisposition supposition for glioma. J Natl Cancer Inst 93:1512-1513.
11. Fioretos T, Panagopoulos I, Lassen C, Swedin A, Billstrom R, Isaksson M, Strombeck B, Olofsson T, Mitelman F, Johansson B. 2001. Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL. Genes Chromosomes Cancer 32:302-310.
12. Fridell RA, Truant R, Thorne L, Benson RE, Cullen BR. 1997. Nuclear import of hnRNP A1 is mediated by a novel cellular cofactor related to karyopherin-beta. J Cell Sci 110:1325-1331.
13. Friedberg T. 2001. Cytochrome P450 polymorphisms as risk factors for steroid hormone-related cancers. Am J Pharmacogenomics 1:83-91.
14. Fritz G, Kaina B. 2001. Transcriptional activation of the small GTPase gene rhoB by genotoxic stress is regulated via a CCAAT element. Nucleic Acids Res 29:792-798.
15. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES. 1999. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286:531-537.
16. Gorlich D, Vogel F, Mills AD, Hartmann E, Laskey RA. 1995. Distinct functions for the two importin subunits in nuclear protein import. Nature 377:246-248.
17. Gray RJ. 1988. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist 16:1141-1154.
18. Greaves M. 2002. Cancer causation: the Darwinian downside of past success? Lancet Oncol 3:244-251.
19. Hahn H. 2001. Genetically determined susceptibility markers in skin cancer and their application to chemoprevention. IARC Sci Publ 154:93-100.
20. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100:57-70.
21. Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA, Donoghue DJ. 2000. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 19:3309-3320.
22. Hemminki K, Xu G, Le Curieux F. 2000. Re: markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst 92:1536-1537.
23. Ihaka R, Gentleman R. 2003. R: A Language for Data Analysis and Graphics. Journal of Computational and Graphical Statistics 5:299-314.
24. Jin W, McCutcheon IE, Fuller GN, Huang ES, Cote GJ. 2000. Fibroblast growth factor receptor-1 alpha-exon exclusion and polypyrimidine tract-binding protein in glioblastoma multiforme tumors. Cancer Res 60:1221-1224.
25. Kielian T, van RN, Hickey WF. 2002. MCP-1 expression in CNS-1 astrocytoma cells: implications for macrophage infiltration into tumors in vivo. J Neurooncol 56:1-12.
26. Knudson AG. 2001. Two genetic hits (more or less) to cancer. Nat Rev Cancer 1:157-162.
27. Krynetskaia NF, Cai X, Nitiss JL, Krynetski EY, Relling MV. 2000. Thioguanine substitution alters DNA cleavage mediated by topoisomerase II. FASEB J 14:2339-2344.
28. Krynetski EY, Evans WE. 2000. Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance. Pharmacology 61:136-146.
29. Krynetski EY, Krynetskaia NF, Bianchi ME, Evans WE. 2003. A nuclear protein complex containing high mobility group proteins B1 and B2, heat shock cognate protein 70, ERp60, and glyceraldehyde-3-phosphate dehydrogenase is involved in the cytotoxic response to DNA modified by incorporation of anticancer nucleoside analogues. Cancer Res 63:100-106.
30. Lennard L, Thomas S, Harrington CI, Maddocks JL. 1985. Skin cancer in renal transplant recipients is associated with increased concentrations of 6-thioguanine nucleotide in red blood cells. Br J Dermatol 113:723-729.
31. Meadows AT, Baum E, Fossati-Bellani F, Green D, Jenkin RDT, Marsden B, Nesbit M, Newton W, Oberlin O, Sallan SG, Siegel S, Strong LC, Voute PA. 1985. Second malignant neoplasms in children: aAn update from the late effects study group. J Clin Oncol 3:532-538.
32. Moroianu J, Hijikata M, Blobel G, Radu A. 1995. Mammalian karyopherin alpha 1 beta and alpha 2 beta heterodimers: alpha 1 or alpha 2 subunit binds nuclear localization signal and beta subunit interacts with peptide repeat-containing nucleoporins. Proc Natl Acad Sci USA 92:6532-6536.
33. Morton NE, Zhang W, Taillon-Miller P, Ennis S, Kwok PY, Collins A. 2001. The optimal measure of allelic association. Proc Natl Acad Sci USA 98:5217-5221.
34. Neglia JP, Meadows AT, Robison LL, Kim TH, Newton WA, Ruymann FB, Sather HN, Hammond GD. 1991. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 325:1330-1336.
35. Nersesyan AK. 2002. Re: Gamma-radiation sensitivity and risk of glioma. J Natl Cancer Inst 94:949.
36. Nygaard R, Garwicz S, Haldorsen T, Hertz H, Jonmundsson GK, Lanning M, Moe PJ. 1991. Second malignant neoplasms in patients treated for childhood leukemia. Acta Paediatr Scand 80:1220-1228.
37. Patel RK, Trivedi AH, Arora DC, Bhatavdekar JM, Patel DD. 1997. DNA repair proficiency in breast cancer patients and their first-degree relatives. Int J Cancer 73:20-24.
38. Pinol-Roma S, Swanson MS, Gall JG, Dreyfuss G. 1989. A novel heterogeneous nuclear RNP protein with a unique distribution on nascent transcripts. J Cell Biol 109:2575-2587.
39. Qian F, Kruse U, Lichter P, Sippel AE. 1995. Chromosomal localization of the four genes (NFIA, B, C, and X) for the human transcription factor nuclear factor I by FISH. Genomics 28:66-73.
40. Relling MV, Yanishevski Y, Nemec J, Evans WE, Boyett JM, Behm FG, Pui C-H. 1998. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 12:346-352.
41. Relling MV, Hancock ML, Boyett JM, Pui C-H, Evans WE. 1999a. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 93:2817-2823.
42. Relling MV, Rubnitz JE, Rivera GK, Boyett JM, Hancock ML, Felix CA, Kun LE, Walter AW, Evans WE, Pui CH. 1999b. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 354:34-39.
43. Russo A, Zanna I, Tubiolo C, Migliavacca M, Bazan V, Latteri MA, Tomasino RM, Gebbia N. 2000. Hereditary common cancers: molecular and clinical genetics. Anticancer Res 20:4841-4851.
44. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO, Weinstein JN. 2000. A gene expression database for the molecular pharmacology of cancer. Nat Genet 24:236-244.
45. Shadan FF, Koziol J. 2000. Induced genome instability as a potential screening test for cancer susceptibility? Med Hypotheses 55:69-72.
46. Shamsher MK, Ploski J, Radu A. 2002. Karyopherin beta 2B participates in mRNA export from the nucleus. Proc NatlAcad Sci USA 99:14195-14199.
47. Sitwala KV, Adams K, Markovitz DM. 2002. YY1 and NF-Y binding sites regulate the transcriptional activity of the dek and dek-can promoter. Oncogene 21:8862-8870.
48. Somerville L, Krynetski EY, Krynetskaia NF, Beger RD, Zhang W, Marhefka CA, Evans WE, Kriwacki RW. 2003. Structure and dynamics of thioguanine-modified duplex DNA. J Biol Chem 278:1005-1011.
49. Swann PF, Waters TR, Moulton DC, Xu Y-Z, Zheng Q, Edwards M, Mace R. 1996. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 273:1109-1111.
50. Thompsen J, Schroder H, Kristinsson J, Madsen B, Szumlanski C, Weinshilboum R, Andersen JB, Schmiegelow K. 1999. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism. Cancer 86:1080-1086.
51. Torpey N, Maher SE, Bothwell AL, Pober JS. 2004. Interferon alpha but not interleukin 12 activates STAT4 signaling in human vascular endothelial cells. J Biol Chem 279:26789-26796.
52. Trokovic R, Trokovic N, Hernesniemi S, Pirvola U, Vogt Weisenhorn DM, Rossant J, McMahon AP, Wurst W, Partanen J. 2003. FGFR1 is independently required in both developing mid- and hindbrain for sustained response to isthmic signals. EMBO J 22:1811-1823.
53. Wiese C, Wilde A, Moore MS, Adam SA, Merdes A, Zheng Y. 2001. Role of importin-beta in coupling Ran to downstream targets in microtubule assembly. Science 291:653-656.
54. Yang MS, Lee J, Ji KA, Min KJ, Lee MA, Jou I, Joe E. 2004. Thrombin induces suppressor of cytokine signaling 3 expression in brain microglia via protein kinase Cdelta activation. Biochem Biophys Res Commun 317:811-816.
55. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, Behm FG, Raimondi SC, Relling MV, Patel A, Cheng C, Campana D, Wilkins D, Zhou X, Li J, Liu H, Pui CH, Evans WE, Naeve C, Wong L, Downing JR. 2002. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1:133-143.
56. Zhang SS, Welte T, Fu XY. 2001. Dysfunction of Stat4 leads to accelerated incidence of chemical-induced thymic lymphomas in mice. Exp Mol Pathol 70:231-238.